Post by BioStock - Connecting Innovation and Capital

@DexTech Medical's clinical study with OsteoDex in myeloma is fully enrolled and the preliminary results are positive. All patients transitioned from progressive to non-progressive stable disease during treatment, and more than 70 percent maintained that stable disease even after treatment ended. BioStock spoke with CEO Anders R Holmberg to find out more. Read more at BioStock: https://lnkd.in/eiqM8ShS